Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dose level 2 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

NCT00874549
View directory record Official record
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 3 Interventional

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B, Placebo
Drug · Other
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

NCT01629758
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 26, 2026, 1:15 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048
View directory record Official record
Conditions
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 26, 2026, 1:15 AM EDT
Recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

NCT03580278
View directory record Official record
Conditions
Psoriasis
Interventions
ABY-035/AFO2
Biological
Lead sponsor
Affibody
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

NCT00876655
View directory record Official record
Conditions
Healthy
Interventions
TR-701 di-sodium phosphate salt, TR-701 free acid phosphate
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Results available

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708
View directory record Official record
Conditions
Obesity
Interventions
maridebart cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Anaheim, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 26, 2026, 1:15 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

NCT02385825
View directory record Official record
Conditions
Ricin Poisoning
Interventions
RVEc
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

NCT00720876
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, vorinostat
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

NCT02039817
View directory record Official record
Conditions
Renal Impairment, Renal Insufficiency, Kidney Disease, Kidney Diseases
Interventions
IDN-6556
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
DeLand, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 26, 2026, 1:15 AM EDT
Not yet recruiting Phase 2 Interventional

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 1:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2

NCT03523663
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
no intervention. measure eye movement data
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
8 Years to 12 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT03730363
View directory record Official record
Conditions
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Pentamidine
Drug
Lead sponsor
Reinhold Munker
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 26, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

NCT00063804
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, AMD070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 26, 2026, 1:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 26, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00061958
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 26, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 26, 2026, 1:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

NCT07143448
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
HS235, Placebo
Biological · Other
Lead sponsor
35Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 1:15 AM EDT